Amundi Trims Holdings in Revvity Inc. $RVTY

Key Points

• Amundi reduced its Revvity stake by 7.2% in the second quarter, selling 12,288 shares and retaining 159,232 shares valued at approximately $17.7 million. Institutional investors and hedge funds collectively own 86.65% of the company.
• Revvity exceeded quarterly expectations, reporting $1.41 in EPS versus the $1.21 consensus and $729.69 million in revenue versus $702.96 million expected. However, revenue declined 1.3% year over year, and the company guided to fiscal 2026 EPS of $5.30–$5.40.
• Analysts remain cautious, with Revvity carrying an average “Hold” rating and a $116.57 price target, below its reported share price of $124.46. The company also declared a quarterly dividend of $0.07 per share, yielding about 0.2% annually.

Amundi lowered its position in Revvity Inc. (NYSE:RVTY - Free Report) by 7.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 159,232 shares of the company's stock after selling 12,288 shares during the quarter. Amundi owned about 0.14% of Revvity worth $17,716,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RVTY. AQR Capital Management LLC raised its position in Revvity by 5.2% in the first quarter. AQR Capital Management LLC now owns 8,449 shares of the company's stock valued at $883,000 after purchasing an additional 420 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Revvity by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company's stock worth $1,246,000 after purchasing an additional 744 shares during the period. Millennium Management LLC grew its holdings in shares of Revvity by 102.0% during the 1st quarter. Millennium Management LLC now owns 69,401 shares of the company's stock worth $7,343,000 after purchasing an additional 35,048 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Revvity by 45.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company's stock worth $64,232,000 after purchasing an additional 189,871 shares during the last quarter. Finally, Focus Partners Wealth increased its position in shares of Revvity by 13.0% during the 1st quarter. Focus Partners Wealth now owns 7,028 shares of the company's stock worth $744,000 after purchasing an additional 811 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Price Performance

RVTY stock opened at $124.46 on Friday. The business has a 50 day moving average price of $117.71 and a 200 day moving average price of $103.21. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36. The stock has a market cap of $13.89 billion, a price-to-earnings ratio of 59.27, a PEG ratio of 2.20 and a beta of 1.09. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $133.00.

Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same period in the previous year, the business earned $1.18 EPS. The business's quarterly revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity's payout ratio is 13.33%.

Analysts Set New Price Targets

RVTY has been the subject of several research analyst reports. Sanford C. Bernstein began coverage on shares of Revvity in a research note on Friday, June 26th. They set a "market perform" rating and a $115.00 target price for the company. Weiss Ratings raised shares of Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 30th. Royal Bank Of Canada initiated coverage on shares of Revvity in a report on Tuesday, September 1st. They issued a "sector perform" rating and a $135.00 price objective on the stock. Wolfe Research assumed coverage on shares of Revvity in a research report on Tuesday, June 2nd. They set a "peer perform" rating for the company. Finally, UBS Group initiated coverage on shares of Revvity in a report on Wednesday. They issued a "neutral" rating and a $140.00 target price for the company. Four analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. Based on data from MarketBeat.com, Revvity presently has an average rating of "Hold" and an average price target of $116.57.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer's Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.